196 related articles for article (PubMed ID: 31472458)
1. Synthesis of a long acting nanoformulated emtricitabine ProTide.
Soni D; Bade AN; Gautam N; Herskovitz J; Ibrahim IM; Smith N; Wojtkiewicz MS; Dyavar Shetty BL; Alnouti Y; McMillan J; Gendelman HE; Edagwa BJ
Biomaterials; 2019 Nov; 222():119441. PubMed ID: 31472458
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation.
Ibrahim IM; Bade AN; Lin Z; Soni D; Wojtkiewicz M; Dyavar Shetty BL; Gautam N; McMillan JM; Alnouti Y; Edagwa BJ; Gendelman HE
Int J Nanomedicine; 2019; 14():6231-6247. PubMed ID: 31496683
[TBL] [Abstract][Full Text] [Related]
3. A long acting nanoformulated lamivudine ProTide.
Smith N; Bade AN; Soni D; Gautam N; Alnouti Y; Herskovitz J; Ibrahim IM; Wojtkiewicz MS; Dyavar Shetty BL; McMillan J; Gendelman HE; Edagwa B
Biomaterials; 2019 Dec; 223():119476. PubMed ID: 31525692
[TBL] [Abstract][Full Text] [Related]
4. Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles.
Krovi SA; Gallovic MD; Keller AM; Bhat M; Tiet P; Chen N; Collier MA; Gurysh EG; Pino EN; Johnson MM; Shamim Hasan Zahid M; Cottrell ML; Pirone JR; Kashuba AD; Kwiek JJ; Bachelder EM; Ainslie KM
Int J Pharm; 2018 Dec; 552(1-2):371-377. PubMed ID: 30308272
[TBL] [Abstract][Full Text] [Related]
5. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies.
Hobson JJ; Al-Khouja A; Curley P; Meyers D; Flexner C; Siccardi M; Owen A; Meyers CF; Rannard SP
Nat Commun; 2019 Mar; 10(1):1413. PubMed ID: 30926773
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Characterization of Long-Acting Darunavir Prodrugs.
Banoub MG; Bade AN; Lin Z; Cobb D; Gautam N; Dyavar Shetty BL; Wojtkiewicz M; Alnouti Y; McMillan J; Gendelman HE; Edagwa B
Mol Pharm; 2020 Jan; 17(1):155-166. PubMed ID: 31742407
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of a long-acting nanoformulated abacavir prodrug.
Singh D; McMillan J; Hilaire J; Gautam N; Palandri D; Alnouti Y; Gendelman HE; Edagwa B
Nanomedicine (Lond); 2016 Aug; 11(15):1913-27. PubMed ID: 27456759
[TBL] [Abstract][Full Text] [Related]
8. Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy.
Frasca K; Morrow M; Coyle RP; Coleman SS; Ellison L; Bushman LR; Kiser JJ; Zheng JH; Mawhinney S; Anderson PL; Castillo-Mancilla J
J Antimicrob Chemother; 2019 May; 74(5):1395-1401. PubMed ID: 30668713
[TBL] [Abstract][Full Text] [Related]
9. Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir.
Gautam N; McMillan JM; Kumar D; Bade AN; Pan Q; Kulkarni TA; Li W; Sillman B; Smith NA; Shetty BLD; Szlachetka A; Edagwa BJ; Gendelman HE; Alnouti Y
Nat Commun; 2021 Jun; 12(1):3453. PubMed ID: 34103484
[TBL] [Abstract][Full Text] [Related]
10. Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV.
Stevens DM; Adiseshaiah P; Dasa SSK; Potter TM; Skoczen SL; Snapp KS; Cedrone E; Patel N; Busman-Sahay K; Rosen EP; Sykes C; Cottrell M; Dobrovolskaia MA; Estes JD; Kashuba ADM; Stern ST
Mol Pharm; 2020 Oct; 17(10):3794-3812. PubMed ID: 32841040
[TBL] [Abstract][Full Text] [Related]
11. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
[TBL] [Abstract][Full Text] [Related]
12. An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.
Mandal S; Belshan M; Holec A; Zhou Y; Destache CJ
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821449
[TBL] [Abstract][Full Text] [Related]
13. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine (Emtriva, FTC).
Liotta DC; Painter GR
Acc Chem Res; 2016; 49(10):2091-2098. PubMed ID: 27704821
[TBL] [Abstract][Full Text] [Related]
15. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
[TBL] [Abstract][Full Text] [Related]
16. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
Zhou T; Su H; Dash P; Lin Z; Dyavar Shetty BL; Kocher T; Szlachetka A; Lamberty B; Fox HS; Poluektova L; Gorantla S; McMillan J; Gautam N; Mosley RL; Alnouti Y; Edagwa B; Gendelman HE
Biomaterials; 2018 Jan; 151():53-65. PubMed ID: 29059541
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.
Puligujja P; Balkundi SS; Kendrick LM; Baldridge HM; Hilaire JR; Bade AN; Dash PK; Zhang G; Poluektova LY; Gorantla S; Liu XM; Ying T; Feng Y; Wang Y; Dimitrov DS; McMillan JM; Gendelman HE
Biomaterials; 2015 Feb; 41():141-50. PubMed ID: 25522973
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection.
Wang LH; Begley J; St Claire RL; Harris J; Wakeford C; Rousseau FS
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1173-82. PubMed ID: 15588339
[TBL] [Abstract][Full Text] [Related]
19. Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants.
Shakil A; Hern FY; Liu C; Temburnikar K; Chambon P; Liptrott N; McDonald TO; Neary M; Owen A; Freel Meyers C; Rannard SP
J Mater Chem B; 2022 Jun; 10(23):4395-4404. PubMed ID: 35604111
[TBL] [Abstract][Full Text] [Related]
20. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
